Mirati Therapeutics, Inc. (MRTX) financial statements (2021 and earlier)

Company profile

Business Address 9393 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,3904152231515712229
Cash and cash equivalents886473310822497
Short-term investments50536919043347323
Receivables2      
Prepaid expense8613222
Other current assets 222111
Other undisclosed current assets3210001
Total current assets:1,4044242271566012533
Noncurrent Assets
Operating lease, right-of-use asset40 
Property, plant and equipment8201110
Long-term investments and receivables16      
Long-term investments16      
Other noncurrent assets9611320
Total noncurrent assets:72821431
TOTAL ASSETS:1,4764322281576312833
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:7148261415105
Accounts payable181694622
Accrued liabilities 21106652
Employee-related liabilities14863321
Other undisclosed accounts payable and accrued liabilities3931000 
Deferred revenue 1
Contract with customer, liability0
Total current liabilities:7149261415105
Noncurrent Liabilities
Long-term debt and lease obligation42      
Operating lease, liability42 
Liabilities, other than long-term debt2110000
Accounts payable and accrued liabilities 11    
Other liabilities2  0000
Total noncurrent liabilities:44110000
Total liabilities:11550271415105
Stockholders' equity
Stockholders' equity attributable to parent1,3613822021434811828
Common stock0000000
Additional paid in capital2,4811,145751594429415261
Accumulated other comprehensive income101099101010
Accumulated deficit(1,130)(772)(559)(461)(390)(307)(242)
Total stockholders' equity:1,3613822021434811828
TOTAL LIABILITIES AND EQUITY:1,4764322281576312833

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:13313    
Operating expenses(383)(225)(116)(72)(84)(65)(39)
Operating loss:(369)(222)(103)(72)(84)(65)(39)
Nonoperating income (expense)12126110(0)
Investment income, nonoperating1310  (1)
Foreign currency transaction gain, before tax      0
Other nonoperating income (expense)1194110(0)
Loss from continuing operations before equity method investments, income taxes:(357)(210)(97)(70)(83)(65)(40)
Other undisclosed loss from continuing operations before income taxes(1)(3)(1)(0)  (4)
Net loss available to common stockholders, diluted:(358)(213)(98)(70)(83)(65)(44)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(358)(213)(98)(70)(83)(65)(44)
Comprehensive loss:(358)(213)(98)(70)(83)(65)(44)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0 (0)(0)00
Comprehensive loss, net of tax, attributable to parent:(358)(213)(98)(70)(83)(65)(44)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: